Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 10/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.49 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581532 | 1.00 | HDAC2 (0.60) | HDAC2HDAC1SCN9APIM3PIM2 | |
| SCHEMBL4581926 | 0.94 | HDAC1 (0.61) | HDAC2HDAC1SCN9AHDAC3 | |
| SCHEMBL4580439 | 0.91 | HDAC2 (0.61) | HDAC2HDAC1SCN9AHDAC3 | |
| SCHEMBL4580443 | 0.91 | HDAC2 (0.61) | HDAC2HDAC1SCN9AHDAC3 | |
| SCHEMBL4578242 | 0.86 | HDAC1 (0.61) | HDAC2HDAC1HDAC3 | |
| SCHEMBL4578247 | 0.86 | HDAC1 (0.61) | HDAC2HDAC1HDAC3 | |
| SCHEMBL4580625 | 0.86 | HDAC1 (0.61) | HDAC2HDAC1HDAC3 | |
| SCHEMBL4580967 | 0.85 | HDAC2 (0.59) | HDAC2HDAC1PIM3PIM2HDAC3 | |
| SCHEMBL4580962 | 0.85 | HDAC2 (0.59) | HDAC2HDAC1PIM3PIM2HDAC3 | |
| SCHEMBL4578126 | 0.84 | HDAC2 (0.62) | HDAC2HDAC1SCN9AHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101466670-B | Inhibitors of histone deacetylase | METHYLGENE INC | 2013-04-17 | — | — | CN | claimed |
| EP-2007720-B1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2013-12-25 | — | — | EP | disclosed |
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| CN-101466670-B | Inhibitors of histone deacetylase | METHYLGENE INC | 2013-04-17 | — | — | CN | disclosed |
| CN-101466670-A | Benzamide derivatives as inhibitors of histone deacetylase | METHYLGENE INC (CA) | 2009-06-24 | — | — | CN | disclosed |
| EP-2007720-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2008-12-31 | — | — | EP | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| WO-2007118137-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HDAC2 5/4885HDAC1 1/4885SCN9A 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.